Vera Therapeutics in the Market Today
Today, many investors in the biotechnology market caused a selloff of Vera Therapeutics (VERA) following its announcement of an exclusive license agreement with Stanford University to acquire a next generation fusion protein targeting BAFF and APRIL, known as VT-109.

VT-109 has wide therapeutic potential across the spectrum of B cell mediated diseases. What Vera Therapeutics . . .